IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Kiniksa Pharmaceuticals International, plc (KNSA) is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases.
Investment Thesis
Kiniksa is a high-growth 'launch story.' Their lead product, ARCALYST, is the first and only FDA-approved therapy for recurrent pericarditis. The clinical data for ARCALYST is exceptional, showing a near-complete elimination of recurrence for patients who were previously suffering from debilitating, chronic inflammation. Because there are no direct competitors, Kiniksa has successfully achieved massive market penetration and rapid revenue growth. Unlike many early-stage biotechs, Kiniksa has a clear and accelerated path to profitability driven by a blockbuster product in a niche, underserved market.
Key Growth Drivers
First-Mover Advantage
As the only approved treatment for a chronic and painful condition, ARCALYST enjoys a monopolistic position and high barriers to entry for any potential future competitors.
Explosive Revenue Growth
The rapid adoption of ARCALYST by cardiologists is driving triple-digit year-over-year revenue growth, providing the company with a massive cash-generating engine.
Expansion into New Indications
Beyond pericarditis, Kiniksa is aggressively testing its pipeline molecules for other massive inflammatory markets, offering significant 'free' upside optionality.
Valuation & Financial Modeling
KNSA is a high-growth asset that should be valued on its peak sales potential. Given the high unmet need and the lack of competition, we believe the current market cap fails to account for the multi-billion dollar long-term potential of ARCALYST and the company's broader anti-inflammatory platform.
Risk Factors & Bear Case
While revenue is growing rapidly, the company is still in the reinvestment phase and may remain GAAP unprofitable for several more quarters. Additionally, any adverse regulatory changes regarding specialty drug pricing would impact their long-term margins.
Conclusion
Kiniksa Pharmaceuticals is a premier growth stock in the biotech sector. It is a 'best-in-class' operator with a clear path to market dominance in chronic inflammation. Rated 'Strong Buy'.
Upcoming Catalysts
No upcoming catalysts identified.
Unlock Investment Thesis
Sign up for free access to institutional-quality research tools.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 41.3GRADE C
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
5.7%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, Kiniksa Pharmaceuticals International, plc (KNSA) receives a "Hold" rating with a composite score of 46.8/100, ranked #421 out of 4446 stocks. Key factor scores: Quality 41/100, Value 48/100, Momentum 68/100. This is quantitative analysis only — not investment advice.
Kiniksa Pharmaceuticals International, plc (KNSA) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Kiniksa Pharmaceuticals International, plc Do?
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda. Kiniksa Pharmaceuticals International, plc (KNSA) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Sanj K. Patel and employs approximately 220 people. With a market capitalization of $3.7B, KNSA is one of the notable companies in the Healthcare sector.
As of April 2026, Kiniksa Pharmaceuticals International, plc receives a Hold rating with a composite score of 46.8/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.KNSA ranks #421 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Kiniksa Pharmaceuticals International, plc ranks #22 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
KNSA Stock Price and 52-Week Range
Kiniksa Pharmaceuticals International, plc (KNSA) currently trades at $47.08. The stock lost $0.25 (0.5%) in the most recent trading session. The 52-week high for KNSA is $49.12, which means the stock is currently trading -4.2% from its annual peak. The 52-week low is $18.25, putting the stock 157.9% above its annual trough. Recent trading volume was 480K shares, suggesting relatively thin trading activity.
Is KNSA Overvalued or Undervalued? — Valuation Analysis
Kiniksa Pharmaceuticals International, plc (KNSA) carries a value factor score of 48/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 116.64x, compared to the Healthcare sector average of 23.63x — a premium of 394%. The price-to-book ratio stands at 6.60x, versus the sector average of 2.75x. The price-to-sales ratio is 6.37x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, KNSA trades at 76.01x EV/EBITDA, versus 6.34x for the sector.
Overall, KNSA's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Kiniksa Pharmaceuticals International, plc (KNSA) earns a quality factor score of 41/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 5.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 4.2% versus the sector average of -33.1%.
On a margin basis, Kiniksa Pharmaceuticals International, plc reports gross margins of 86.5%, compared to 71.5% for the sector. The operating margin is 6.8% (sector: -66.1%). Net profit margin stands at 4.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 66.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
KNSA Debt, Balance Sheet, and Financial Health
Kiniksa Pharmaceuticals International, plc has a debt-to-equity ratio of 35.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.79x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $175M.
KNSA has a beta of 0.51, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Kiniksa Pharmaceuticals International, plc is 69/100, reflecting average volatility within the normal range for its sector.
Kiniksa Pharmaceuticals International, plc Revenue and Earnings History — Quarterly Trend
In TTM 2026, Kiniksa Pharmaceuticals International, plc reported revenue of $588M and earnings per share (EPS) of $0.80. Net income for the quarter was $32M. Gross margin was 86.5%. Operating income came in at $48M.
In FY 2025, Kiniksa Pharmaceuticals International, plc reported revenue of $678M and earnings per share (EPS) of $0.80. Net income for the quarter was $59M. Gross margin was 88.5%. Revenue grew 60.1% year-over-year compared to FY 2024. Operating income came in at $77M.
In Q3 2025, Kiniksa Pharmaceuticals International, plc reported revenue of $181M and earnings per share (EPS) of $0.25. Net income for the quarter was $18M. Gross margin was 88.8%. Revenue grew 61.2% year-over-year compared to Q3 2024. Operating income came in at $24M.
In Q2 2025, Kiniksa Pharmaceuticals International, plc reported revenue of $157M and earnings per share (EPS) of $0.24. Net income for the quarter was $18M. Gross margin was 88.1%. Revenue grew 44.3% year-over-year compared to Q2 2024. Operating income came in at $20M.
Over the past 8 quarters, Kiniksa Pharmaceuticals International, plc has demonstrated a growth trajectory, with revenue expanding from $109M to $588M. Investors analyzing KNSA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
KNSA Dividend Yield and Income Analysis
Kiniksa Pharmaceuticals International, plc (KNSA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
KNSA Momentum and Technical Analysis Profile
Kiniksa Pharmaceuticals International, plc (KNSA) has a momentum factor score of 68/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 11/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
KNSA vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing KNSA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full KNSA vs S&P 500 (SPY) comparison to assess how Kiniksa Pharmaceuticals International, plc stacks up against the broader market across all factor dimensions.
KNSA Next Earnings Date
No upcoming earnings date has been announced for Kiniksa Pharmaceuticals International, plc (KNSA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy KNSA? — Investment Thesis Summary
Kiniksa Pharmaceuticals International, plc presents a balanced picture with arguments on both sides. Price momentum is positive at 68/100, suggesting the trend favors buyers. Low volatility (stability score 69/100) reduces downside risk.
In summary, Kiniksa Pharmaceuticals International, plc (KNSA) earns a Hold rating with a composite score of 46.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on KNSA stock.
We'll email you when stocks you follow change their composite rating.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
66.5%
Sector: 10.6%
+525% VS SCTR
Gross Margin
Core pricing power
86.5%
Sector: 71.5%
+21% VS SCTR
Operating Margin
Operating efficiency
6.8%
Sector: -66.1%
-110% VS SCTR
Net Margin
Bottom-line conversion
4.1%
Sector: -58.7%
-107% VS SCTR
Return on Equity
Equity capital efficiency
5.7%
Sector: -43.5%
-113% VS SCTR
Return on Assets
Asset base utilization
4.2%
Sector: -33.1%
-113% VS SCTR
Debt/Equity
Financial leverage load
35.0%
Sector: 32.0%
IN LINE
Dividend Yield
Direct cash return
0.0%
Sector: 0.0%
-NaN% VS SCTR
+140%
Price / Sales
6.4x
+284%
Kiniksa Pharmaceuticals International, plc exhibits a 479% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
4.2%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
86.5%
Sector: 71.5%
Operating Margin
Core business profitability
6.8%
Sector: -66.1%
Net Margin
Bottom-line profitability
4.1%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.